术后化疗对食管胃腺癌术前化疗后手术患者生存的影响
基于英格兰和威尔士2012–2018年全国审计数据,纳入4139例接受术前化疗后手术的食管胃腺癌患者,其中1593例(38.5%)接受术后化疗。逆概率治疗加权后,术后化疗组中位生存62.7个月 vs 未化疗组50.4个月(HR 0.84,95%CI 0.77–0.94;P=0.001)。
要点
- 接受术前化疗+手术的食管胃腺癌患者中仅38.5%接受术后化疗。
- 加权后术后化疗组中位生存62.7个月 vs 未化疗组50.4个月,HR 0.84。
- 几乎所有患者(96.7%)接受铂类三联方案,FLOT仅占3.3%。
核心结论
- 术后化疗可改善接受术前化疗和手术的食管胃腺癌患者的总生存。
研究设计与样本
- 基于英格兰和威尔士全国审计的 population-based 数据集,纳入2012–2018年诊断的食管、胃食管交界或胃腺癌患者,均接受术前化疗后手术,共4139例。
- 术后化疗定义为术后90天内接受全身化疗,采用逆概率治疗加权比较术后化疗与观察的效果。
主要发现
- 4139例中1593例(38.5%)接受术后化疗。
- 4004例(96.7%)接受铂类三联方案,FLOT用于3.3%。
- 术后化疗组患者更年轻、ASA分级更低、手术并发症更少,肿瘤特征相似。
- 加权后术后化疗组中位生存62.7个月 vs 未化疗组50.4个月(HR 0.84,95%CI 0.77–0.94;P=0.001)。
临床怎么用
- 对于接受术前化疗后手术的食管胃腺癌患者,术后化疗与总生存改善相关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Perioperative chemotherapy is widely used in the treatment of oesophagogastric adenocarcinoma (OGAC) with a substantial survival benefit over surgery alone. However, the postoperative part of these regimens is given in less than half of patients, reflecting uncertainty among clinicians about its benefit and poor postoperative patient fitness. This study estimated the effect of postoperative chemotherapy after surgery for OGAC using a large population-based data set. METHODS: Patients with adenocarcinoma of the oesophagus, gastro-oesophageal junction or stomach diagnosed between 2012 and 2018, who underwent preoperative chemotherapy followed by surgery, were identified from a national-level audit in England and Wales. Postoperative therapy was defined as the receipt of systemic chemotherapy within 90 days of surgery. The effectiveness of postoperative chemotherapy compared with observation was estimated using inverse propensity treatment weighting. RESULTS: Postoperative chemotherapy was given to 1593 of 4139 patients (38.5 per cent) included in the study. Almost all patients received platinum-based triplet regimens (4004 patients, 96.7 per cent), with FLOT used in 3.3 per cent. Patients who received postoperative chemotherapy were younger, with a lower ASA grade, and were less likely to have surgical complications, with similar tumour characteristics. After weighting, the median survival time after postoperative chemotherapy was 62.7 months compared with 50.4 months without chemotherapy (hazard ratio 0.84, 95 per cent c.i. 0.77 to 0.94; P = 0.001). CONCLUSION: This study has shown that postoperative chemotherapy improves overall survival in patients with OGAC treated with preoperative chemotherapy and surgery.
引用
- Rahman S, Thomas B, Maynard N, et al. Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery. Br J Surg. 2022. PMID: 34910129. doi:10.1093/bjs/znab427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。